These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 26883935)

  • 1. Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials.
    D'Angelo FA; Antolino L; La Rocca M; Petrucciani N; Magistri P; Aurello P; Ramacciato G
    Med Oncol; 2016 Mar; 33(3):28. PubMed ID: 26883935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma.
    Du L; DeFoe M; Ruzinova MB; Olsen JR; Wang-Gillam A
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):717-26. PubMed ID: 26226906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation.
    Hoffe S; Rao N; Shridhar R
    Semin Radiat Oncol; 2014 Apr; 24(2):113-25. PubMed ID: 24635868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.
    Huan L; Yu F; Cao D; Zhou H; Qin M; Cao Y
    PLoS One; 2024; 19(3):e0295983. PubMed ID: 38451955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist?
    Piątek M; Kuśnierz K; Bieńkowski M; Pęksa R; Kowalczyk M; Nawrocki S
    Crit Rev Oncol Hematol; 2019 Mar; 135():95-102. PubMed ID: 30819452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
    Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
    van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
    Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis.
    Uson Junior PLS; Carvalho L; Fernandes MLC; Botrus G; de Souza Martins R; da Silva EF; Dos Santos SSMB; Taniwaki L; Taranto P; Dutra ACP; de Oliveira Filho JB; Araujo SEA; Moura F
    Sci Rep; 2022 Aug; 12(1):13592. PubMed ID: 35948602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
    Scheufele F; Friess H
    Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer.
    Keedy VL; Berlin J
    Curr Treat Options Oncol; 2006 Sep; 7(5):381-8. PubMed ID: 16904055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.
    Mavros MN; Moris D; Karanicolas PJ; Katz MHG; O'Reilly EM; Pawlik TM
    JAMA Surg; 2021 Jul; 156(7):663-672. PubMed ID: 33787841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant and neoadjuvant approaches in pancreatic cancer.
    Conroy T; Lambert A; Ducreux M
    Curr Opin Oncol; 2023 Jul; 35(4):326-333. PubMed ID: 37222189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Pancreatic Adenocarcinoma: A Decision Analysis.
    Sharma G; Whang EE; Ruan DT; Ito H
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1229-37. PubMed ID: 26152276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Developments and controversies in neoadjuvant therapy for resectable pancreatic cancer].
    Bai XL; Li X; Liang TB
    Zhonghua Wai Ke Za Zhi; 2020 Jul; 58(7):486-489. PubMed ID: 32610415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary trials evaluating neoadjuvant therapy for resectable pancreatic cancer.
    Chawla A
    J Surg Oncol; 2021 May; 123(6):1423-1431. PubMed ID: 33831254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages.
    Tang K; Lu W; Qin W; Wu Y
    Pancreatology; 2016; 16(1):28-37. PubMed ID: 26687001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of neoadjuvant therapy in pancreatic cancer: a review.
    Russo S; Ammori J; Eads J; Dorth J
    Future Oncol; 2016 Mar; 12(5):669-85. PubMed ID: 26880384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma.
    Motoi F; Unno M
    Jpn J Clin Oncol; 2020 May; 50(5):483-489. PubMed ID: 32083290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies: Where Are We?
    Wolff RA
    Surg Clin North Am; 2018 Feb; 98(1):95-111. PubMed ID: 29191281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.
    Heinrich S; Lang H
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.